Special Issue "Therapeutic Potential of Natural Products in Internal Diseases"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 775

Special Issue Editors

Departament 1 Medical Semiology, Universitatea de Medicina si Farmacie Carol Davila din Bucuresti, Bucharest, Romania
Interests: phytotherapy; herbal medicine; integrative medicine; pshychosomatics; internal medicine; nephrology; cardiovascular; neurovascular; diabetes
Physiology Department, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: atherosclerosis; coronary artery disease; scavenger receptors; anesthetic preconditioning; endothelial progenitor cells; non coding RNA; nutraceuticals; phytocompounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last decades tremendous progress has been made in the discovery of new drugs for the treatment of internal diseases, changing the prognostics and course of these diseases. However, important, often severe or even life-threatening side effects mar the employment of these novel treatments. Despite the statements in the guidelines, patients are not actually encouraged to perform the much-needed lifestyle changes that would make at least some of these new drugs less necessary, if at all, especially for the management of cardiovascular diseases, diabetes, obesity, dyslipidemia, and chronic obstructive lung disease. There are many instances of inappropriate employment of conventional drugs in the treatment of symptoms/disorders for which those drugs are not indicated, such as antibiotics for viral diseases, coronary heart disease medication for unspecific (including psychosomatic) chest pain, blood pressure-lowering medication for emotion-related fluctuations in blood pressure, etc., and many honest practitioners acknowledge that they should use something else, but lack the trust in or knowledge of alternative therapies. A large segment of the population prefers alternative treatments, one of the most popular being herbal treatments. Individuals relying on alternative therapies are more amenable to health-promoting lifestyle changes.

Unfortunately, among the researchers and practitioners of mainstream medicine there is a high degree of skepticism about the effectiveness of natural products, given the paucity and low quality of evidence supporting it. Let us, those that understand the considerable and insufficiently tapped potential of natural products, provide high-quality studies and reviews promoting the use of these products.

Dr. Dorin Dragoş
Dr. Adelina Vlad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • medicinal plants
  • phytotherapy
  • herbal treatment
  • natural products
  • herbalism
  • traditional medicine
  • cardiovascular disease
  • lung disease
  • liver disease
  • gastrointestinal disease
  • kidney disease
  • obesity
  • diabetes
  • rheumatological disease

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


19 pages, 2502 KiB  
Evaluating the Potential of Plukenetia volubilis Linneo (Sacha Inchi) in Alleviating Cardiovascular Disease Risk Factors: A Mini Review
Pharmaceuticals 2023, 16(11), 1588; https://doi.org/10.3390/ph16111588 - 09 Nov 2023
Viewed by 466
Plukenetia volubilis Linneo or Sacha Inchi (SI), a traditional natural remedy indigenous to Peru and Brazil, has garnered global attention due to its exceptional nutritional composition. Its protective effects against various non-communicable diseases, notably cardiovascular disease (CVD), have become a subject of interest [...] Read more.
Plukenetia volubilis Linneo or Sacha Inchi (SI), a traditional natural remedy indigenous to Peru and Brazil, has garnered global attention due to its exceptional nutritional composition. Its protective effects against various non-communicable diseases, notably cardiovascular disease (CVD), have become a subject of interest in recent research. This comprehensive review summarizes the existing evidence from 15 relevant articles concerning the impact of SI on common CVD risk factors, including dyslipidemia, obesity, diabetes, and hypertension. The relevant articles were derived from comprehensive searches on PubMed, Scopus, Google Scholar, and Web of Science using predefined criteria and keywords related to the topic. Overall, SI demonstrated positive effects in attenuating dyslipidemia, obesity, diabetes, and hypertension. The multifaceted mechanisms responsible for the protective effects of SI against these CVD risk factors are primarily attributed to its antioxidative and anti-inflammatory properties. While preclinical studies dominate the current scientific literature on SI, there are limited clinical trials to corroborate these findings. Therefore, future well-designed, large-scale randomized clinical trials are highly recommended to establish the efficacy of SI and determine its optimal dosage, potential drug and food interactions, and practical integration into preventive strategies and dietary interventions for the high-risk populations. Full article
(This article belongs to the Special Issue Therapeutic Potential of Natural Products in Internal Diseases)
Show Figures

Figure 1

Back to TopTop